Loading stock data…
$0.78+0.00 (+0.26%)
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
iBio, Inc. in the Healthcare sector is trading at $0.78 with a market capitalization of $77M. Wall Street consensus targets $5.69 (9 analysts), implying a +626.7% move over the next 12 months. The stock is currently near its 52-week low of $0.73, remaining 55.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $100,000↓ | $200,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.38M↑ | -$8.37M↑ | -$9.45M↓ | -$5.95M↓ | -$5.20M |
| Net Income | -$10.60M↓ | -$7.73M↑ | -$8.99M↓ | -$5.72M↓ | -$5.16M |
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved C...